Kazia Therapeutics Ltd (KZIA) stock
KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
$5.49+0.18 (+3.39%)
Close on Nov 18, 2026Market cap $8.89MP/E –Yield –
Kazia Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.04 AUD. The highest annual figure on record is -0.04 AUD in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | -0.04 AUD | – |
| FY2024 | Jun 30, 2024 | -0.10 AUD | – |
| FY2023 | Jun 30, 2023 | -0.11 AUD | – |
| FY2022 | Jun 30, 2022 | -0.19 AUD | – |
| FY2021 | Jun 30, 2021 | -0.07 AUD | – |
| FY2020 | Jun 30, 2020 | -0.17 AUD | – |
| FY2019 | Jun 30, 2019 | -17.86 AUD | – |
| FY2018 | Jun 30, 2018 | -12.48 AUD | – |
| FY2017 | Jun 30, 2017 | -2.28 AUD | – |
| FY2016 | Jun 30, 2016 | -2.82 AUD | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?